Charts

Gainers Cerberus Cyber Sentinel Corporation (NASDAQ: CISO) shares rose 147% to $0.5682 in pre-market trading. Cerberus Cyber ...

InvestorPlace - Stock Market News, Stock Advice & Trading Tips We're starting off the day with a look at the biggest pre-market stock movers traders need to know about on Tuesday morning! The post Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Tuesday appeared first on InvestorPlace. More From InvestorPlace Buy This $5 Stock BEFORE This Apple Project Goes Live The Best $1 Investment You Can Make Today It doesn’t matter if you have $500 or $5 million. Do this now. Massive Bear Market “Divergence Event” Ahead… And The #1 Way to Play It

Gainers Adial Pharmaceuticals, Inc. (NASDAQ: ADIL) rose 64.6% to $0.6912 in pre-market trading after the company provided an ...

Gainers Reata Pharmaceuticals Inc (NASDAQ: RETA) shares jumped 171.5% to $84.67 after the company reported the FDA approval of ...

Gainers Reata Pharmaceuticals (NASDAQ:RETA) shares rose 175.1% to $85.75 during Wednesday's pre-market session. The company's market ...

Gainers Reata Pharmaceuticals Inc (NASDAQ: RETA) rose 140.8% to $75.06 in pre-market trading after the company reported the FDA ...

InvestorPlace - Stock Market News, Stock Advice & Trading Tips It's time to start the day with another breakdown of the biggest pre-market stock movers traders need to know about on Wednesday! The post Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Wednesday appeared first on InvestorPlace. More From InvestorPlace Buy This $5 Stock BEFORE This Apple Project Goes Live The Best $1 Investment You Can Make Today It doesn’t matter if you have $500 or $5 million. Do this now. Massive Bear Market “Divergence Event” Ahead… And The #1 Way to Play It

Gainers China SXT Pharmaceuticals (NASDAQ:SXTC) shares moved upwards by 19.8% to $0.47 during Tuesday's after-market session. At the ...

Gainers Cardio Diagnostics Holdings, Inc. (NASDAQ: CDIO) shares jumped 153% to $3.24 after the company announced the launch of ...

Gainers Cardio Diagnostics Hldgs (NASDAQ:CDIO) stock moved upwards by 137.1% to $3.17 during Tuesday's regular session. Trading volume ...

Catalyst Biosciences Inc (NASDAQ: CBIO) shares are soaring Tuesday morning after GC Biopharmasigned an Asset Purchase Agreement ...

InvestorPlace - Stock Market News, Stock Advice & Trading Tips AdaptHealth (AHCO) stock is falling on Tuesday following the release of the company's earnings report for the fourth quarter of 2022. The post Why Is AdaptHealth (AHCO) Stock Down 22% Today? appeared first on InvestorPlace. More From InvestorPlace Buy This $5 Stock BEFORE This Apple Project Goes Live The Best $1 Investment You Can Make Today It doesn’t matter if you have $500 or $5 million. Do this now. Massive Bear Market “Divergence Event” Ahead… And The #1 Way to Play It

InvestorPlace - Stock Market News, Stock Advice & Trading Tips Aptinyx (APTX) stock is taking a beating on Tuesday after the company revealed poor results from a Phase 2 clinical trial. The post Why Is Aptinyx (APTX) Stock Down 64% Today? appeared first on InvestorPlace. More From InvestorPlace Buy This $5 Stock BEFORE This Apple Project Goes Live The Best $1 Investment You Can Make Today It doesn’t matter if you have $500 or $5 million. Do this now. Massive Bear Market “Divergence Event” Ahead… And The #1 Way to Play It

InvestorPlace - Stock Market News, Stock Advice & Trading Tips Intelligent Living (ILAG) stock is heading higher on Tuesday after the company announced plans to develop home security devices. The post Why Is Intelligent Living (ILAG) Stock Up 38% Today? appeared first on InvestorPlace. More From InvestorPlace Buy This $5 Stock BEFORE This Apple Project Goes Live The Best $1 Investment You Can Make Today It doesn’t matter if you have $500 or $5 million. Do this now. Massive Bear Market “Divergence Event” Ahead… And The #1 Way to Play It

Gainers Catalyst Biosciences (NASDAQ:CBIO) shares moved upwards by 59.1% to $0.38 during Tuesday's pre-market session. The market value ...

InvestorPlace - Stock Market News, Stock Advice & Trading Tips Catalyst Biosciences (CBIO) stock is rocketing higher on Tuesday after the company agreed to an asset purchase agreement with GC Biopharma. The post Why Is Catalyst Biosciences (CBIO) Stock Up 55% Today? appeared first on InvestorPlace. More From InvestorPlace Buy This $5 Stock BEFORE This Apple Project Goes Live The Best $1 Investment You Can Make Today It doesn’t matter if you have $500 or $5 million. Do this now. Massive Bear Market “Divergence Event” Ahead… And The #1 Way to Play It

SOUTH SAN FRANCISCO, Calif., Feb. 28, 2023 (GLOBE NEWSWIRE) -- Catalyst Biosciences Inc. (NASDAQ: CBIO) (“Catalyst” or “the Company”) today provided two corporate updates. In connection with the Company’s previously announced asset purchase agreement with GNI Group Ltd (“GNI Group”) and GNI Hong Kong Limited (together “GNI”) to purchase all of the assets and intellectual property rights primarily related to GNI’s proprietary hydronidone compound outside of China (collectively, the “F351 Assets”)

Gainers Catalyst Biosciences Inc (NASDAQ: CBIO) rose 105% to $0.49 in pre-market trading. South Korea's GC Biopharma said it ...

InvestorPlace - Stock Market News, Stock Advice & Trading Tips It's time to start the day with a breakdown of the biggest pre-market stock movers traders need to know about on Thursday! The post Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Thursday appeared first on InvestorPlace. More From InvestorPlace Buy This $5 Stock BEFORE This Apple Project Goes Live The Best $1 Investment You Can Make Today It doesn’t matter if you have $500 or $5 million. Do this now. Massive Bear Market “Divergence Event” Ahead… And The #1 Way to Play It

Gainers Celyad Oncology SA (NASDAQ: CYAD) rose 221.7% to $2.57 in pre-market trading after gaining 21% on Friday. Celyad Oncology, ...

Gainers SmileDirectClub (NASDAQ:SDC) stock increased by 47.0% to $0.71 during Monday's regular session. SmileDirectClub's stock is ...

Gainers Shuttle Pharmaceuticals (NASDAQ:SHPH) stock increased by 41.8% to $2.51 during Monday's pre-market session. The company's ...

U.S. stocks traded higher toward the end of trading, with the Nasdaq Composite gaining around 50 points on Friday. The Dow traded up ...

Gainers TC BioPharm (Holdings) (NASDAQ:TCBP) stock rose 90.6% to $8.5 during Friday's regular session. As of 12:30 EST, TC BioPharm ...

Gainers Jasper Therapeutics (NASDAQ:JSPR) stock rose 32.1% to $2.18 during Friday's pre-market session. The market value of their ...

InvestorPlace - Stock Market News, Stock Advice & Trading Tips We're starting the final day of trading this week with a breakdown of the biggest pre-market stock movers for Friday morning! The post Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Friday appeared first on InvestorPlace. More From InvestorPlace Buy This $5 Stock BEFORE This Apple Project Goes Live The Best $1 Investment You Can Make Today Early Bitcoin Millionaire Reveals His Next Big Crypto Trade “On Air” It doesn’t matter if you have $500 or $5 million. Do this now.

Former Attorney General of Louisiana Charles C. Foti, Jr., Esq. and the law firm of Kahn Swick & Foti, LLC (“KSF”) are investigating Catalyst Biosciences, Inc. (NasdaqCM: CBIO) in connection with its acquisition of the F351 program, a next-generation fibrosis drug, from GNI Group Ltd. and, in a separate transaction, its acquisition of a controlling interest in Beijing Continent for 6,266,521 shares of common stock and 12,340 shares of a new series of preferred stock (Series X) with economic rights equivalent to Catalyst’s common stock. Each share of Series X preferred stock is convertible into 10,000 shares of common stock, subject to stockholder approval under Nasdaq rules and subject to a beneficial ownership conversion blocker. KSF is seeking to determine whether the transaction and the process that led to it are adequate and fair to the Company’s shareholders.

Halper Sadeh LLC, an investor rights law firm, is investigating whether the merger of Catalyst Biosciences, Inc. (NASDAQ: CBIO) and GNI Group Ltd. is fair to Catalyst shareholders.

Acquires F351, a Phase 3 Drug to Treat Fibrosis Will Acquire Controlling Interest in Continent, a China-Based Commercial Pharma Company, from the GNI Group in Subsequent Transaction Announces $7.5 Million Special Dividend and Contingent Value Right (CVR) CBIO Stockholder Meeting Planned for 2023 CBIO to Host Conference Call Today at 8:00 a.m. E.T. SOUTH SAN FRANCISCO, Calif. and TOKYO, Dec. 27, 2022 (GLOBE NEWSWIRE) -- Catalyst Biosciences, Inc. (NASDAQ: CBIO) (“Catalyst”) and GNI Group Ltd. (21

Catalyst Biosciences ( NASDAQ:CBIO ) Third Quarter 2022 Results Key Financial Results Net loss: US$4.88m (loss narrowed...

Over the last year, a good number of insiders have significantly increased their holdings in Catalyst Biosciences, Inc...

Catalyst Biosciences's (NASDAQ:CBIO) short percent of float has fallen 48.42% since its last report. The company recently reported that ...

SOUTH SAN FRANCISCO, Calif., Sept. 01, 2022 (GLOBE NEWSWIRE) -- Catalyst Biosciences, Inc. (NASDAQ: CBIO) (“Catalyst,” the “Company” or “we”) today announced that the ex-dividend date for the special, one-time cash dividend of $1.43 per share to holders of the Company’s Common Stock previously disclosed by the Company will be September 21, 2022. The dividend is payable on September 20, 2022 to stockholders of record at the close of business on September 6, 2022. Stockholders of record on the rec

SOUTH SAN FRANCISCO, Calif., Aug. 25, 2022 (GLOBE NEWSWIRE) -- Catalyst Biosciences, Inc. (NASDAQ: CBIO) (“Catalyst,” the “Company” or “we”) today announced that the Board of Directors has declared a special, one-time cash dividend of $1.43 per share to holders of the Company’s Common Stock. The dividend is payable on September 20, 2022 to stockholders of record at the close of business on September 6, 2022. The aggregate amount of the payment to be made in connection with this special dividend

Catalyst Biosciences, Inc. ( NASDAQ:CBIO ) shareholders will doubtless be very grateful to see the share price up 45...

Company to Announce a Record Date for Initial Distribution in Due CourseSOUTH SAN FRANCISCO, Calif., Aug. 19, 2022 (GLOBE NEWSWIRE) -- Catalyst Biosciences, Inc. (NASDAQ: CBIO) (“Catalyst,” the “Company” or “we”) today announced that JDS1, LLC, one of the Company’s stockholders, has dismissed its lawsuits against the Company. “With the JDS1 litigation behind us, the Board of Directors will be meeting to determine the details of an initial distribution of capital, and we will communicate this inf

SOUTH SAN FRANCISCO, Calif., Aug. 15, 2022 (GLOBE NEWSWIRE) -- Catalyst Biosciences, Inc. (NASDAQ: CBIO) (the “Company” or “we”) today announced its operating and financial results for the second quarter ended June 30, 2022. “We were very pleased to have completed the sale of our complement portfolio during the second quarter to Vertex Pharmaceuticals Incorporated (NASDAQ: VRTX) (“Vertex”) for $60.0 million in cash with up to $5.0 million of that amount due in May 2023. This transaction was the

JDS1, LLC (“JDS1”), which collectively with the other reporting persons in its Section 13(d) group, beneficially owns approximately 8.4% of the outstanding common stock of Catalyst Biosciences, Inc. (NASDAQ: CBIO) (“Catalyst” or the “Company”), commented today on its previously announced withdrawal of the director nominations and other proposed business that it had intended to bring before the upcoming 2022 Annual Meeting of Stockholders of Catalyst Biosciences, Inc.

Encourages Stockholders to Vote on the WHITE Proxy CardSOUTH SAN FRANCISCO, Calif., Aug. 10, 2022 (GLOBE NEWSWIRE) -- Catalyst Biosciences, Inc. (NASDAQ: CBIO) (the “Company,” “Catalyst” or “we”) announced that it has received a notice from JDS1, LLC (“JDS1”) that JDS1 has withdrawn the nominations of Shelly C. Lombard, Matthew Stecker, and Igor Volshteyn (the “Withdrawn Candidates”) for election to the Catalyst Board of Directors at the Catalyst 2022 annual meeting of stockholders (the “2022 An

ISS and Glass Lewis Highlight That Stockholders Are Best Served by Allowing the Incumbent Board to Pursue Its Cash Distribution Plan Catalyst Urges Stockholders to VOTE “FOR” All of the Company’s Nominees SOUTH SAN FRANCISCO, Calif., Aug. 03, 2022 (GLOBE NEWSWIRE) -- Catalyst Biosciences, Inc. (NASDAQ: CBIO) (the “Company,” “Catalyst” or “we”) today announced that leading proxy advisory firms Institutional Shareholder Services Inc. (“ISS”) and Glass Lewis have recommended that Catalyst stockhold

Provides Details on Current Board’s Cash Distribution Plan and Efforts to Maximize the Amount of Cash Available for Distribution Company Commits to Distributing $45 Million to Stockholders in an Initial Distribution, if Proxy Contest and Litigation End Soon, and Without Much Additional Expense Highlights the Concerning Connections Between JDS1’s Nominees and the Singer Family Stockholders Urged to VOTE “FOR” ALL of Catalyst’s Nominees, Who Are Committed to the Company’s Cash Distribution Plan, o

JEC Capital Partners Agrees to Vote Its Shares in Favor of Catalyst’s Nominees at the Company’s 2022 Annual Meeting Michael Torok from JEC Appointed as an Observer to the Transaction Committee of the Board of Directors Company Has Committed to Announcing a Record Date for a Substantial Distribution of Cash to Stockholders as Soon as Litigation and Proxy Fight are Resolved Catalyst Calls Upon JDS1 to Drop Its Litigation and Proxy Contest so the Company Can Expeditiously Execute Its Cash Distribut

JDS1, LLC, which collectively with the other participants in its solicitation beneficially owns approximately 8.4% of the outstanding common stock of Catalyst Biosciences, Inc. (NASDAQ: CBIO) (“Catalyst” or the “Company”), today announced that it has filed its definitive proxy statement with the U.S. Securities and Exchange Commission and sent a letter to its fellow stockholders. JDS1 is urging shareholders to vote on the GOLD proxy card to elect its slate of three highly-qualified nominees – Shelly Lombard, Matthew Stecker, and Igor Volshteyn – to Catalyst’s eight-member Board of Directors at Catalyst’s 2022 Annual Meeting of Stockholders to be held in person on August 15, 2022. In its letter to stockholders, included below, JDS1 again calls for Catalyst to firmly, and unequivocally, commit to a distribution to stockholders of most of its available cash at the earliest possible time.

Reiterates the Board’s Commitment to Expeditiously Distributing All of the Company’s Available Cash to Stockholders, Net of Liabilities and Obligations Warns Stockholders that JDS1 May Have Ulterior Motives in Running a Proxy Contest: Gaining Control of the Company’s Cash and Other Assets for JDS1’s Own Benefit Stockholders Urged to VOTE “FOR” ALL of Catalyst’s Nominees, Who Are Committed to the Company’s Cash Distribution Plan, on the WHITE Proxy Card SOUTH SAN FRANCISCO, Calif., July 19, 2022

Here is how Adicet Bio, Inc. (ACET) and Catalyst Biosciences, Inc. (CBIO) have performed compared to their sector so far this year.

Court Denies JDS1’s Motion for Expedited Proceedings Board Reiterates Commitment to Distributing Cash to Stockholders Once Potential Liability and Expenses Associated with Stockholder Litigation and Proxy Contest Are Known SOUTH SAN FRANCISCO, Calif., July 06, 2022 (GLOBE NEWSWIRE) -- Catalyst Biosciences, Inc. (NASDAQ: CBIO) (the “Company” or “we”) today announced that the Delaware Court of Chancery has denied the motion for expedited proceedings in the action brought by the plaintiff, JDS1, LL

Gainers Allena Pharmaceuticals, Inc. (NASDAQ: ALNA) shares surged 114.3% to close at $0.2550 on Wednesday after the company ...

Gainers Allena Pharmaceuticals, Inc. (NASDAQ: ALNA) jumped 207% to $0.3650 after the company announced it has terminated its ...

Board is Committed to Maximizing the Amount of Cash the Company Distributes to Stockholders Decision Follows Recent Sale of Certain Assets and Extensive Engagement with Stockholders Board Will Set Initial Distribution Date and Amount Once Potential Liability and Expenses Associated with Stockholder Litigation and Proxy Contest Are Known SOUTH SAN FRANCISCO, Calif., June 29, 2022 (GLOBE NEWSWIRE) -- Catalyst Biosciences, Inc. (NASDAQ: CBIO) (the “Company” or “we”) today announced its intention to

Here is how Catalyst Biosciences, Inc. (CBIO) and Humana (HUM) have performed compared to their sector so far this year.

Here's a roundup of top developments in the biotech space over the last 24 hours: Stocks In Focus Precision BioSciences Shares ...

Biotech stocks advanced in the week ended May 27, tracking the overall positive sentiment of the broader market. Notwithstanding the ...

Gainers Adicet Bio, Inc. (NASDAQ: ACET) rose 16% to $11.90 in pre-market trading after reporting positive clinical update from ...

Gainers Creatd, Inc. (NASDAQ: CRTD) shares jumped 58.5% to close at $1.28 on Thursday. Creatd’s board approved a rights ...

Gainers CynergisTek, Inc. (NYSE: CTEK) jumped 100% to $1.18 after the company entered into a definitive agreement to be acquired ...

On Modnay, shares of Catalyst Biosciences, Inc. (NASDAQ: CBIO) experienced volatile short activity. After the activity, the stock price ...

Gainers BIMI International Medical Inc. (NASDAQ: BIMI) shares rose 136.4% to $1.43 in pre-market trading. BOQI International ...

Gainers Catalyst Biosciences, Inc. (NASDAQ: CBIO) gained 234.2% to close at $1.27 after the company announced it sold its ...

InvestorPlace - Stock Market News, Stock Advice & Trading Tips Catalyst Biosciences (CBIO) stock is rocketing higher on Monday after announcing the sale of its protease medicines portfolio. The post Why Is Catalyst Biosciences (CBIO) Stock Soaring 170% Today? appeared first on InvestorPlace. More From InvestorPlace Stock Prodigy Who Found NIO at $2… Says Buy THIS It doesn’t matter if you have $500 in savings or $5 million. Do this now. Get in Now on Tiny $3 ‘Forever Battery’ Stock Early Bitcoin Millionaire Reveals His Next Big Crypto Trade “On Air”

Catalyst Biosciences Inc(NASDAQ: CBIO) hasagreed to sellits portfolio of protease medicines that regulate ...

Catalyst Biosciences Inc (NASDAQ: CBIO) shares are trading higher by 180.26% at $1.06 after the company announced it sold its complement ...

Catalyst Biosciences (NASDAQ:CBIO) reported its Q1 earnings results on Monday, May 9, 2022 at 08:30 AM. Here's what ...

According to data from Benzinga Pro, during Q4, Catalyst Biosciences's (NASDAQ:CBIO) reported sales totaled $2.44 million. Despite a ...